Fortis Healthcare has made the audio recording of its investors and analysts meet publicly available on its website. The meeting, held on Friday, August 07, 2026, at 12:00 PM (IST), focused on the company's unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This release ensures transparency for shareholders and market participants seeking detailed insights into the Q1FY27 performance.

The disclosure was filed with the National Stock Exchange of India Ltd and BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Satyendra Chauhan, Company Secretary & Compliance Officer of Fortis Healthcare Limited, signed the communication on August 07, 2026. The filing confirms that the audio recording is accessible via the company’s investor relations portal.

Key Details of the Disclosure

Accessing the Recording

Investors and analysts can access the audio recording through the official Fortis Healthcare website. The link directs users to the investor presentations and transcripts section, specifically labeled for the Q1FY27 earnings call in August 2026. This resource allows stakeholders to review management commentary and question-and-answer sessions from the event.

What the Numbers Show

While this specific filing serves as a procedural disclosure for the audio recording, it highlights the company's adherence to regulatory timelines for post-earnings communication. The focus on both standalone and consolidated results indicates a comprehensive review of the group's financial health for the period ending June 30, 2026.

Fortis Healthcare has provided guidance on the profitability of its diagnostic operations, indicating that EBITDA margins from this segment are expected to remain in the range of 24-25% over the next five years. The outlook was shared during a concall update, offering investors and analysts a view into the company's medium-term expectations for its diagnostics business.

Diagnostic Segment EBITDA Margin Guidance

The management commentary focused specifically on the diagnostic operations vertical, projecting a sustained margin band for the foreseeable future. The following table summarises the key guidance detail shared during the concall:

The 24-25% EBITDA margin guidance for diagnostic operations reflects the company's assessment of the segment's earnings potential over an extended period. This range serves as a benchmark for evaluating the performance of the diagnostics business going forward.

Key Takeaways from the Concall Update

• Fortis Healthcare expects diagnostic EBITDA margins to stay within the 24-25% band over the next five years.
• The guidance was communicated as part of a concall update, providing direct management commentary on segment-level profitability.
• The outlook is specific to diagnostic operations and does not reference the company's broader consolidated financials.

The management's guidance underscores a stable margin expectation for the diagnostics segment, with the 24-25% range representing the projected profitability corridor for this business vertical over the stated horizon.